Ahmedabad-based pharma major Cadila Healthcare, which covered a long journey from being a Rs 250-crore company in 1995 to the Rs 9,800-crore behemoth it is today, feels the road ahead lies in biosimilars. The company's chairman and managing director Pankaj R Patel tells Sohini Das how he expects the turnover from biosimilars to grow to 20 per cent of its revenues in the long term.
We have no plan at this moment to raise the money, but it is an enabling provision. If you are acquiring anything, you might need to raise some money. Once you zero in on any target, it is too late to raise the funds then. Deals can happen in one month and some deals can take years. You never know how soon or how fast can the deal materialise.
We did an acquisition of the animal health business of Zoetis, making a strong position in the animal health business in India for Zydus. With this acquisition, we became one of the top companies in the sector in India. It’s more strategic from the size perspective, and we did not have a manufacturing asset in the animal health business. We now also have the manufacturing capability and that would help us increase our exports going forward. That's the whole rationale behind this acquisition, and we believe business can grow 10-15 per cent going forward.
Comments